Search Articles
SAN DIEGO – Amylin Pharmaceuticals is selling itself too cheaply to Bristol-Myers Squibb, for $5.3 billion or $31 a share, according to a shareholders class action in Federal Court.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.